Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 adjunctive lumateperone in bipolar depression
2018-002749-12Phase 3Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lumateperone in bipolar disorder (BD), bipolar I disorder and Bipolar II disorder (BP-II) (3 arms), sponsored by Intra-Cellular Therapies. Primary endpoint: Primary efficacy endpoint. Started Dec 2018; status: completed.
02
Drugs
lumateperone
03
Conditions
bipolar disorder (BD)bipolar I disorderBipolar II disorder (BP-II)
Beyond the preview
Go deeper on 2018-002749-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002749-12.